FDA Safety Review of Abortion Pill Mifepristone Extended Into Next Year
The U.S. Food and Drug Administration (FDA) announced in a court filing that its ongoing safety review of the nation's main abortion pill, mifepristone, will continue into next year. While a safety study is expected by mid-December, a report and…
Philadelphia, PA, October 7, 2026 — The U.S. Food and Drug Administration (FDA) has indicated that its comprehensive safety review of mifepristone, a medication widely used for abortion, will extend into next year. The agency disclosed this timeline in a recent court filing, providing an update on the status of its evaluation of the drug’s safety profile.
A key component of this review, a safety study, is anticipated to be completed by mid-December. However, the subsequent report detailing the findings of this study, along with any potential regulatory decisions regarding new restrictions on mifepristone, is not expected to be released until March 2027. This timeline suggests a prolonged period before any definitive outcomes or policy changes are announced by the FDA concerning the medication.
Mifepristone is a prescription drug used in combination with another medication, misoprostol, to end a pregnancy. The FDA’s ongoing safety review is a standard process but has gained heightened attention given the ongoing legal and political discussions surrounding reproductive healthcare access in the United States.
The court filing did not specify the reasons for the extended timeline for the final report and potential decisions, beyond indicating the progression of the safety study. The agency’s commitment to a thorough review process is implied by the scheduled completion dates. Further updates on the review’s progress are expected as the mid-December deadline for the safety study approaches.
Story summarized from the original created by MATTHEW PERRONE on www.inquirer.com, see more information here.
Media gallery
